Charles River Laboratories International (NYSE:CRL) Releases FY 2026 Earnings Guidance

Charles River Laboratories International (NYSE:CRL) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 11.450-11.450 for the period, compared to the consensus earnings per share estimate of 11.330. The company issued revenue guidance of $3.9 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $295.30 on Friday. The company has a fifty day simple moving average of $269.08 and a 200 day simple moving average of $212.48. Charles River Laboratories International has a 12-month low of $144.26 and a 12-month high of $303.30. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a market cap of $14.10 billion, a P/E ratio of -60.89, a PEG ratio of 2.80 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. During the same period last year, the company earned $3.12 earnings per share. The business’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts predict that Charles River Laboratories International will post 11.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on CRL shares. Royal Bank Of Canada upped their target price on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a research report on Thursday, August 6th. Argus set a $330.00 target price on Charles River Laboratories International in a research note on Thursday, September 17th. Finally, TD Cowen upped their target price on Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a report on Monday, August 10th. Eleven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $273.81.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Victoria Creamer sold 4,179 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the completion of the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 165,990 shares of company stock worth $42,606,388 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International News Roundup

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River raised its fiscal 2026 adjusted EPS guidance to approximately $11.45, above the analyst consensus of $11.33. Revenue guidance of roughly $3.9 billion was reaffirmed and remains broadly in line with expectations. Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections
• Positive Sentiment: The company unveiled 2030 growth targets at its Investor Day, giving investors a longer-term framework for revenue and earnings expansion. The targets, together with the improved 2026 earnings outlook, appear to have driven the positive market reaction. Charles River Laboratories Stock Rises After Unveiling 2030 Growth Targets
• Positive Sentiment: Reports characterized the Investor Day outlook as promising, with management emphasizing future growth opportunities and reaffirming confidence in the fiscal 2026 plan. CRL subsequently traded near its 52-week high, suggesting investors viewed the update as a catalyst for renewed optimism. Charles River rises on Investor Day on promising 2026 outlook

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.